High glucose enhances interleukin-6-induced vascular endothelial growth factor 165 expression via activation of Gp130-mediated p44/42 MAPK-CCAAT/enhancer binding protein signaling in gingival fibroblasts

被引:40
作者
Omori, K [1 ]
Naruishi, K [1 ]
Nishimura, F [1 ]
Yamada-Naruishi, H [1 ]
Takashiba, S [1 ]
机构
[1] Okayama Univ, Grad Sch Med & Dent, Dept Pathophysiol Periodontal Sci, Okayama 7008525, Japan
关键词
D O I
10.1074/jbc.M311688200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Diabetic patients are susceptible to severe inflammatory periodontitis manifesting as swollen gingiva with bleeding, but the underlying mechanism is not well understood. Our purpose was to determine the effect of a high glucose (HG) condition on the interleukin-6/soluble interleukin-6 receptor (IL-6/sIL-6R)-induced activation of signaling and vascular endothelial growth factor (VEGF) expression in human gingival fibroblasts (HGFs). In this study, HGFs were cultured for at least two passages under a normal glucose (NG; 5.5 mm) condition or high glucose (25 mm) condition. Importantly, the HG condition significantly induced expression of gp130 mRNA in HGFs compared with levels in control cells. Consistent with the expression of its mRNA, the HG condition also increased the expression of gp130 protein, and phosphorylation of the tyrosine residue by gp130 was enhanced significantly by IL-6/sIL-6R stimulation. Furthermore, the HG condition enhanced the IL-6/sIL-6R-induced phosphorylation of p44/42 MAPK and led to subsequent activation of CCAAT/enhancer binding protein in nuclei. In contrast, there was no significant difference in phosphorylation of JNK between the HG and NG condition. Interestingly, HGFs increased IL-6/sIL-6R,induced VEGF165 mRNA expression and VEGF165 secretion under the HG condition compared with levels under the NG condition. In contrast, the induction of VEGF165 secretion was partially inhibited by PD98059 (selective p44/42 MAPK inhibitor) under the HG condition. In addition, the VEGF165 secretion was completely inhibited by the combination of PD98059 and SP600125 (JNK inhibitor). Our findings suggest that the HG condition indirectly increases VEGF expression via activation of gp130-mediated p44/42 MAPK-CCAAT/enhancer binding protein signaling in HGFs. Thus, elevated VEGF secretion in HGFs under the HG condition may play a role in the development of the severe periodontitis observed in diabetic patients.
引用
收藏
页码:6643 / 6649
页数:7
相关论文
共 35 条
[1]   NF-IL6 and NF-κB in cytokine gene regulation [J].
Akira, S ;
Kishimoto, T .
ADVANCES IN IMMUNOLOGY, VOL 65, 1997, 65 :1-46
[2]   PD-098059 IS A SPECIFIC INHIBITOR OF THE ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE IN-VITRO AND IN-VIVO [J].
ALESSI, DR ;
CUENDA, A ;
COHEN, P ;
DUDLEY, DT ;
SALTIEL, AR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (46) :27489-27494
[3]   Commentary - Glucose, VEGF-A, and diabetic complications [J].
Benjamin, LE .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (04) :1181-1184
[4]   Cytokine gene expression in chronic periodontitis [J].
Bickel, M ;
Axtelius, B ;
Solioz, C ;
Attström, R .
JOURNAL OF CLINICAL PERIODONTOLOGY, 2001, 28 (09) :840-847
[5]   Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy [J].
Cameron, NE ;
Eaton, SEM ;
Cotter, MA ;
Tesfaye, S .
DIABETOLOGIA, 2001, 44 (11) :1973-1988
[6]   Potentiation of lipopolysaccharide-inducible cyclooxygenase 2 expression by C2-ceramide via c-Jun N-terminal kinase-mediated activation of CCAAT/enhancer binding protein β in macrophages [J].
Cho, YH ;
Lee, CH ;
Kim, SG .
MOLECULAR PHARMACOLOGY, 2003, 63 (03) :512-523
[7]   Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes [J].
Funamoto, M ;
Fujio, Y ;
Kunisada, K ;
Negoro, S ;
Tone, E ;
Osugi, T ;
Hirota, H ;
Izumi, M ;
Yoshizaki, K ;
Walsh, K ;
Kishimoto, T ;
Yamauchi-Takihara, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (14) :10561-10566
[8]   Relationship between vascular endothelial growth factor and interleukin-6 in diabetic retinopathy [J].
Funatsu, H ;
Yamashita, H ;
Shimizu, E ;
Kojima, R ;
Hori, S .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2001, 21 (05) :469-477
[9]   NEW DEVELOPMENTS OF A TRANSCRIPTION FACTORS DATABASE [J].
GHOSH, D .
TRENDS IN BIOCHEMICAL SCIENCES, 1991, 16 (11) :445-447
[10]   GINGIVAL INTERLEUKIN-6 CONCENTRATION FOLLOWING PHASE-I THERAPY [J].
GUILLOT, JL ;
POLLOCK, SM ;
JOHNSON, RB .
JOURNAL OF PERIODONTOLOGY, 1995, 66 (08) :667-672